# Apotransferrin in Atransferrinemia

> **NCT01797055** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Prothya Biosolutions** · enrollment: 5 (actual)

## Conditions studied

- Congenital Atransferrinemia

## Interventions

- **DRUG:** Human apotransferrin

## Key facts

- **NCT ID:** NCT01797055
- **Lead sponsor:** Prothya Biosolutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2010-12
- **Primary completion:** 2022-03-31
- **Final completion:** 2028-01
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01797055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01797055, "Apotransferrin in Atransferrinemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01797055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*